Literature DB >> 15037869

Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden.

G Bart, M Heilig, K S LaForge, L Pollak, S M Leal, J Ott, M J Kreek.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15037869      PMCID： PMC6141020          DOI： 10.1038/sj.mp.4001504

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN： 1359-4184            Impact factor:   15.992


× No keyword cloud information.
  10 in total

Review 1.  Opioid receptor and peptide gene polymorphisms: potential implications for addictions.

Authors:  K S LaForge; V Yuferov; M J Kreek
Journal:  Eur J Pharmacol       Date:  2000-12-27       Impact factor: 4.432

Review 2.  Pharmacotherapy of addictions.

Authors:  Mary Jeanne Kreek; K Steven LaForge; Eduardo Butelman
Journal:  Nat Rev Drug Discov       Date:  2002-09       Impact factor: 84.694

Review 3.  Chromosome mapping of gene loci affecting morphine and amphetamine responses in BXD recombinant inbred mice.

Authors:  J K Belknap; J C Crabbe
Journal:  Ann N Y Acad Sci       Date:  1992-06-28       Impact factor: 5.691

4.  The mu-opioid receptor gene polymorphism (A118G) alters HPA axis activation induced by opioid receptor blockade.

Authors:  Gary S Wand; Mary McCaul; Xioaju Yang; Joanna Reynolds; Deidre Gotjen; Shing Lee; Ahmed Ali
Journal:  Neuropsychopharmacology       Date:  2002-01       Impact factor: 7.853

5.  Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene.

Authors:  H W Matthes; R Maldonado; F Simonin; O Valverde; S Slowe; I Kitchen; K Befort; A Dierich; M Le Meur; P Dollé; E Tzavara; J Hanoune; B P Roques; B L Kieffer
Journal:  Nature       Date:  1996-10-31       Impact factor: 49.962

6.  Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1).

Authors:  Carlos A Hernandez-Avila; Gary Wand; Xingguang Luo; Joel Gelernter; Henry R Kranzler
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2003-04-01       Impact factor: 3.568

7.  Morphine self-administration in mu-opioid receptor-deficient mice.

Authors:  A Becker; G Grecksch; R Brödemann; J Kraus; B Peters; H Schroeder; W Thiemann; H H Loh; V Höllt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2000-06       Impact factor: 3.000

8.  Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction.

Authors:  C Bond; K S LaForge; M Tian; D Melia; S Zhang; L Borg; J Gong; J Schluger; J A Strong; S M Leal; J A Tischfield; M J Kreek; L Yu
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

9.  A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients.

Authors:  David W Oslin; Wade Berrettini; Henry R Kranzler; Helen Pettinati; Joel Gelernter; Joseph R Volpicelli; Charles P O'Brien
Journal:  Neuropsychopharmacology       Date:  2003-06-18       Impact factor: 7.853

10.  Co-occurrence of abuse of different drugs in men: the role of drug-specific and shared vulnerabilities.

Authors:  M T Tsuang; M J Lyons; J M Meyer; T Doyle; S A Eisen; J Goldberg; W True; N Lin; R Toomey; L Eaves
Journal:  Arch Gen Psychiatry       Date:  1998-11
  10 in total
  75 in total

Review 1.  Introduction to deep sequencing and its application to drug addiction research with a focus on rare variants.

Authors:  Shaolin Wang; Zhongli Yang; Jennie Z Ma; Thomas J Payne; Ming D Li
Journal:  Mol Neurobiol       Date:  2013-08-30       Impact factor: 5.590

2.  Genomewide linkage scan for opioid dependence and related traits.

Authors:  Joel Gelernter; Carolien Panhuysen; Marsha Wilcox; Victor Hesselbrock; Bruce Rounsaville; James Poling; Roger Weiss; Susan Sonne; Hongyu Zhao; Lindsay Farrer; Henry R Kranzler
Journal:  Am J Hum Genet       Date:  2006-03-16       Impact factor: 11.025

3.  Mu opioid receptor A118G polymorphism in association with striatal opioid neuropeptide gene expression in heroin abusers.

Authors:  Katarina Drakenberg; Andrej Nikoshkov; Monika Cs Horváth; Pernilla Fagergren; Anna Gharibyan; Kati Saarelainen; Sadia Rahman; Ingrid Nylander; Georgy Bakalkin; Jovan Rajs; Eva Keller; Yasmin L Hurd
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-08       Impact factor: 11.205

Review 4.  Candidate gene polymorphisms predicting individual sensitivity to opioids.

Authors:  Shinya Kasai; Masakazu Hayashida; Ichiro Sora; Kazutaka Ikeda
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-11-13       Impact factor: 3.000

5.  The neural circuitry underlying reinstatement of heroin-seeking behavior in an animal model of relapse.

Authors:  J L Rogers; S Ghee; R E See
Journal:  Neuroscience       Date:  2007-10-22       Impact factor: 3.590

Review 6.  An overview of the genetics of substance use disorders.

Authors:  H M Lachman
Journal:  Curr Psychiatry Rep       Date:  2006-04       Impact factor: 5.285

7.  Association between two mu-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence.

Authors:  Huiping Zhang; Xingguang Luo; Henry R Kranzler; Jaakko Lappalainen; Bao-Zhu Yang; Evgeny Krupitsky; Edwin Zvartau; Joel Gelernter
Journal:  Hum Mol Genet       Date:  2006-02-13       Impact factor: 6.150

Review 8.  Symbiotic relationship of pharmacogenetics and drugs of abuse.

Authors:  Joni L Rutter
Journal:  AAPS J       Date:  2006-03-24       Impact factor: 4.009

9.  Variants of opioid system genes are associated with non-dependent opioid use and heroin dependence.

Authors:  Matthew Randesi; Wim van den Brink; Orna Levran; Peter Blanken; Eduardo R Butelman; Vadim Yuferov; Joel Correa da Rosa; Jurg Ott; Jan M van Ree; Mary Jeanne Kreek
Journal:  Drug Alcohol Depend       Date:  2016-09-05       Impact factor: 4.492

Review 10.  Peter Riederer "70th birthday" neurobiological foundations of modern addiction treatment.

Authors:  Christian Jacob
Journal:  J Neural Transm (Vienna)       Date:  2012-08-19       Impact factor: 3.575
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.